Progression elevated gene‐3, PEG‐3, induces genomic instability in rodent and human tumor cells

Genomic instability is a fundamental component of cancer progression. Subtraction hybridization identified a novel rodent gene, progression elevated gene‐3 (PEG‐3) whose expression directly correlates with cancer aggressiveness and progression. Moreover, ectopic expression of PEG‐3 in rodent or human tumor cells produces an aggressive transformed phenotype. We demonstrate that PEG‐3 expression in rodent tumor cells correlates directly with genomic instability as characterized by alterations in chromosome composition and structure. Additionally, elevated endogenous or ectopic expression of PEG‐3 in rodent and human tumor cells, respectively, enhances gene amplification, as monitored by resistance to methothrexate (MTX) and amplification of the dihydrofolate reductase (dhfr) gene. Stable expression of PEG‐3 in normal cloned rat embryo fibroblast (CREF) cells marginally elevates MTX resistance, but morphology remains unaltered and anchorage independence is not induced, suggesting that these phenotypes are separable in immortal cells and gene amplification may precede the acquisition of morphological and oncogenic transformation. The present studies document that stable, inducible, and transient expression of PEG‐3 in cancer cells augments genomic instability. In these contexts, one mechanism by which PEG‐3 influences cancer progression may be by preferentially facilitating the development of genomic changes in evolving cancer cells. © 2002 Wiley‐Liss, Inc.

[1]  Z. Su,et al.  A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Michael R. Speicher,et al.  Securin Is Required for Chromosomal Stability in Human Cells , 2001, Cell.

[3]  Z. Su,et al.  PEA3 sites within the progression elevated gene-3 (PEG-3) promoter and mitogen-activated protein kinase contribute to differential PEG-3 expression in Ha-ras and v-raf oncogene transformed rat embryo cells. , 2001, Nucleic acids research.

[4]  P. Fisher,et al.  Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells , 2000, Oncogene.

[5]  B. Trask,et al.  Amplification of the human dihydrofolate reductase gene via double minutes is initiated by chromosome breaks. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. May,et al.  Cell cycle control and cancer. , 2000, Pathologie-biologie.

[7]  Z. Su,et al.  PEG-3, a nontransforming cancer progression gene, is a positive regulator of cancer aggressiveness and angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. DePinho,et al.  Use of the human EF-1alpha promoter for expression can significantly increase success in establishing stable cell lines with consistent expression: a study using the tetracycline-inducible system in human cancer cells. , 1999, Nucleic acids research.

[9]  W. Coleman,et al.  The role of genomic instability in human carcinogenesis. , 1999, Anticancer research.

[10]  R. Fishel,et al.  Genomic instability: first step to carcinogenesis. , 1999, Anticancer research.

[11]  A. Fornace,et al.  Leukemic HRX Fusion Proteins Inhibit GADD34-Induced Apoptosis and Associate with the GADD34 and hSNF5/INI1 Proteins , 1999, Molecular and Cellular Biology.

[12]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[13]  Z. Su,et al.  The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Z. Su,et al.  Reciprocal subtraction differential RNA display: an efficient and rapid procedure for isolating differentially expressed gene sequences. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Brown,et al.  The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34 , 1997, Journal of virology.

[16]  T. Tlsty,et al.  Identification of additional complementation groups that regulate genomic instability , 1997, Genes, chromosomes & cancer.

[17]  Z. Su,et al.  Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Fornace,et al.  Mammalian GADD34, an Apoptosis- and DNA Damage-inducible Gene* , 1997, The Journal of Biological Chemistry.

[19]  Z. Su,et al.  The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Hoffman,et al.  The carboxyl terminus of the murine MyD116 gene substitutes for the corresponding domain of the gamma(1)34.5 gene of herpes simplex virus to preclude the premature shutoff of total protein synthesis in infected human cells , 1996, Journal of virology.

[21]  Z. Su,et al.  Transcriptional switching model for the regulation of tumorigenesis and metastasis by the ha-ras oncogene - transcriptional changes in the ha-ras tumor-suppressor gene lysyl oxidase. , 1995, International journal of oncology.

[22]  B. Roizman,et al.  Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Gershengorn,et al.  Expression of thyrotropin-releasing hormone receptors by adenovirus-mediated gene transfer reveals that thyrotropin-releasing hormone desensitization is cell specific. , 1994, Molecular pharmacology.

[24]  Z. Su,et al.  Induction of transformation progression in type 5 adenovirus-transformed rat embryo cells by a cloned protein kinase C beta 1 gene and reversal of progression by 5-azacytidine. , 1994, Oncogene.

[25]  K. Kohn,et al.  The gadd and MyD genes define a novel set of mammalian genes encoding acidic proteins that synergistically suppress cell growth , 1994, Molecular and cellular biology.

[26]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[28]  Z. Su,et al.  Analysis of viral and cellular gene expression during progression and suppression of the transformed phenotype in type 5 adenovirus-transformed rat embryo cells. , 1991, Oncogene.

[29]  L. Loeb,et al.  Mutator phenotype may be required for multistage carcinogenesis. , 1991, Cancer research.

[30]  J. Bishop.  Molecular themes in oncogenesis , 1991, Cell.

[31]  C. Marshall.  Tumor suppressor genes , 1991, Cell.

[32]  D. Liebermann,et al.  Sequence of MyD116 cDNA: a novel myeloid differentiation primary response gene induced by IL6. , 1990, Nucleic acids research.

[33]  G. Duigou,et al.  Suppression of the progression phenotype in somatic cell hybrids occurs in the absence of altered adenovirus type 5 gene expression , 1990, Molecular and cellular biology.

[34]  D. Liebermann,et al.  Complexity of the immediate early response of myeloid cells to terminal differentiation and growth arrest includes ICAM-1, Jun-B and histone variants. , 1990, Oncogene.

[35]  G. Duigou,et al.  Suppression of the Progression Phenotype by 5‐Azacytidine in Rat Embryo Cells Doubly Transformed by Type 5 Adenovirus and the Ha‐ras Oncogene a , 1989 .

[36]  A. Fornace,et al.  DNA damage-inducible transcripts in mammalian cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[37]  F. Graham,et al.  A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. , 1988, Virology.

[38]  P. Fisher,et al.  Reversibility of progression of the transformed phenotype in Ad5-transformed rat embryo cells. , 1985, Science.

[39]  T. Tlsty,et al.  UV radiation facilitates methotrexate resistance and amplification of the dihydrofolate reductase gene in cultured 3T6 mouse cells , 1984, Molecular and cellular biology.

[40]  R T Schimke,et al.  Gene amplification, drug resistance, and cancer. , 1984, Cancer research.

[41]  F. Volkert,et al.  The genetic analysis of recombination using adenovirus overlapping terminal DNA fragments. , 1983, Virology.

[42]  P. Fisher,et al.  Analysis of type 5 adenovirus transformation with a cloned rat embryo cell line (CREF). , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Fisher,et al.  Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-transformed rat embryo cells , 1979, Cell.

[44]  P. Fisher,et al.  Tumour promoters enhance anchorage-independent growth of adenovirus-transformed cells without altering the integration pattern of viral sequences , 1979, Nature.

[45]  N. Goldstein,et al.  Phenotypic properties and tumor promotor-induced alterations in rat embryo cells transformed by adenovirus. , 1979, Cancer research.

[46]  P. Fisher,et al.  Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[47]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[48]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[49]  T. Tlsty.  Genomic instability and its role in neoplasia. , 1997, Current topics in microbiology and immunology.

[50]  M. Taira,et al.  Gene Amplification , 2020, Definitions.